Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of  Five Eastern Asian Countries

ConclusionTreatment of ACS for 12  months with ticagrelor is not a cost-effective option for the prevention of thrombotic events in East Asia.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research